Home > Publications Database > Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear Palsy. > print

001     169142
005     20240722121855.0
024 7 _ |a 10.3390/ijms232314554
|2 doi
024 7 _ |a pmid:36498882
|2 pmid
024 7 _ |a pmc:PMC9738832
|2 pmc
024 7 _ |a 1422-0067
|2 ISSN
024 7 _ |a 1661-6596
|2 ISSN
024 7 _ |a altmetric:138767676
|2 altmetric
037 _ _ |a DZNE-2023-00021
041 _ _ |a English
082 _ _ |a 540
100 1 _ |a Simoes, Fabio A
|0 0000-0001-7630-0091
|b 0
245 _ _ |a Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear Palsy.
260 _ _ |a Basel
|c 2022
|b Molecular Diversity Preservation International
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1721636180_12031
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Objective markers for the neurodegenerative disorder progressive supranuclear palsy (PSP) are needed to provide a timely diagnosis with greater certainty. Non-coding RNA (ncRNA), including microRNA, piwi-interacting RNA, and transfer RNA, are good candidate markers in other neurodegenerative diseases, but have not been investigated in PSP. Therefore, as proof of principle, we sought to identify whether they were dysregulated in matched serum and cerebrospinal fluid (CSF) samples of patients with PSP. Small RNA-seq was undertaken on serum and CSF samples from healthy controls (n = 20) and patients with PSP (n = 31) in two cohorts, with reverse transcription-quantitative PCR (RT-qPCR) to confirm their dysregulation. Using RT-qPCR, we found in serum significant down-regulation in hsa-miR-92a-3p, hsa-miR-626, hsa-piR-31068, and tRNA-ValCAC. In CSF, both hsa-let-7a-5p and hsa-piR-31068 showed significant up-regulation, consistent with their changes observed in the RNA-seq results. Interestingly, we saw no correlation in the expression of hsa-piR-31068 within our matched serum and CSF samples, suggesting there is no common dysregulatory mechanism between the two biofluids. While these changes were in a small cohort of samples, we have provided novel evidence that ncRNA in biofluids could be possible diagnostic biomarkers for PSP and further work will help to expand this potential.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a PSP
|2 Other
650 _ 7 |a RNA-seq
|2 Other
650 _ 7 |a biomarker
|2 Other
650 _ 7 |a non-coding RNA
|2 Other
650 _ 7 |a progressive supranuclear palsy
|2 Other
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a MicroRNAs
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Supranuclear Palsy, Progressive: diagnosis
|2 MeSH
650 _ 2 |a Supranuclear Palsy, Progressive: genetics
|2 MeSH
650 _ 2 |a Biomarkers
|2 MeSH
650 _ 2 |a MicroRNAs: genetics
|2 MeSH
650 _ 2 |a Down-Regulation
|2 MeSH
700 1 _ |a Joilin, Greig
|0 0000-0001-5827-6382
|b 1
700 1 _ |a Peters, Oliver
|0 P:(DE-2719)2811024
|b 2
|u dzne
700 1 _ |a Schneider, Luisa-Sophie
|0 0000-0001-5822-1744
|b 3
700 1 _ |a Priller, Josef
|0 P:(DE-2719)2811122
|b 4
|u dzne
700 1 _ |a Spruth, Eike Jakob
|0 P:(DE-2719)2812446
|b 5
|u dzne
700 1 _ |a Vogt, Ina Rosemarie
|0 P:(DE-2719)2811226
|b 6
|u dzne
700 1 _ |a Kimmich, Okka
|0 P:(DE-2719)9002382
|b 7
|u dzne
700 1 _ |a Spottke, Annika
|0 P:(DE-2719)2811324
|b 8
|u dzne
700 1 _ |a Hoffmann, Daniel C
|0 P:(DE-2719)2812665
|b 9
|u dzne
700 1 _ |a Falkenburger, Björn
|0 P:(DE-2719)2814178
|b 10
|u dzne
700 1 _ |a Brandt, Moritz
|0 P:(DE-2719)2812107
|b 11
|u dzne
700 1 _ |a Prudlo, Johannes
|0 P:(DE-2719)2380559
|b 12
|u dzne
700 1 _ |a Brockmann, Kathrin
|0 P:(DE-2719)2811916
|b 13
|u dzne
700 1 _ |a Fries, Franca Laura
|0 P:(DE-2719)9001603
|b 14
|u dzne
700 1 _ |a Rowe, James B
|b 15
700 1 _ |a Church, Alistair
|b 16
700 1 _ |a Respondek, Gesine
|0 P:(DE-2719)2811600
|b 17
|u dzne
700 1 _ |a Newbury, Sarah F
|b 18
700 1 _ |a Leigh, P Nigel
|0 0000-0002-6702-0378
|b 19
700 1 _ |a Morris, Huw R
|b 20
700 1 _ |a Höglinger, Günter
|0 P:(DE-2719)2811373
|b 21
|u dzne
700 1 _ |a Hafezparast, Majid
|b 22
773 _ _ |a 10.3390/ijms232314554
|g Vol. 23, no. 23, p. 14554 -
|0 PERI:(DE-600)2019364-6
|n 23
|p 14554
|t International journal of molecular sciences
|v 23
|y 2022
|x 1422-0067
856 4 _ |u https://pub.dzne.de/record/169142/files/DZNE-2023-00021.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/169142/files/DZNE-2023-00021.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:169142
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2811024
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2811122
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2812446
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2811226
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)9002382
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2811324
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2812665
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2814178
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2812107
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2380559
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)2811916
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)9001603
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)2811600
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 21
|6 P:(DE-2719)2811373
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-25
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2022-09-04T08:27:04Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-25
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J MOL SCI : 2021
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2022-09-04T08:27:04Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2022-09-04T08:27:04Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-25
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-25
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-25
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-25
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J MOL SCI : 2021
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-25
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2022-09-04T08:27:04Z
920 1 _ |0 I:(DE-2719)1810002
|k AG Dirnagl
|l Vascular Pathology
|x 0
920 1 _ |0 I:(DE-2719)5000007
|k AG Priller
|l Translational Neuropsychiatry
|x 1
920 1 _ |0 I:(DE-2719)1811005
|k AG Endres
|l Interdisciplinary Dementia Research
|x 2
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies Bonn
|l Patient Studies Bonn
|x 3
920 1 _ |0 I:(DE-2719)1011401
|k Clinical Research Platform (CRP)
|l Clinical Research Platform (CRP)
|x 4
920 1 _ |0 I:(DE-2719)1710012
|k AG Falkenburger
|l Translational Parkinson Research
|x 5
920 1 _ |0 I:(DE-2719)1710008
|k AG Donix
|l Clinical Planning and Intersite Group
|x 6
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 7
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 8
920 1 _ |0 I:(DE-2719)1110002
|k AG Höglinger 1
|l Translational Neurodegeneration
|x 9
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 10
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1810002
980 _ _ |a I:(DE-2719)5000007
980 _ _ |a I:(DE-2719)1811005
980 _ _ |a I:(DE-2719)1011101
980 _ _ |a I:(DE-2719)1011401
980 _ _ |a I:(DE-2719)1710012
980 _ _ |a I:(DE-2719)1710008
980 _ _ |a I:(DE-2719)1510100
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a I:(DE-2719)1110002
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21